These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 26708068)

  • 1. Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer's disease and type 2 diabetes.
    Infante-Garcia C; Ramos-Rodriguez JJ; Galindo-Gonzalez L; Garcia-Alloza M
    Psychoneuroendocrinology; 2016 Mar; 65():15-25. PubMed ID: 26708068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer's disease.
    Ramos-Rodriguez JJ; Jimenez-Palomares M; Murillo-Carretero MI; Infante-Garcia C; Berrocoso E; Hernandez-Pacho F; Lechuga-Sancho AM; Cozar-Castellano I; Garcia-Alloza M
    Psychoneuroendocrinology; 2015 Dec; 62():69-79. PubMed ID: 26254770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.
    Infante-Garcia C; Ramos-Rodriguez JJ; Hierro-Bujalance C; Ortegon E; Pickett E; Jackson R; Hernandez-Pacho F; Spires-Jones T; Garcia-Alloza M
    Mol Neurobiol; 2018 Jul; 55(7):6130-6144. PubMed ID: 29224179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes.
    Carranza-Naval MJ; Del Marco A; Hierro-Bujalance C; Alves-Martinez P; Infante-Garcia C; Vargas-Soria M; Herrera M; Barba-Cordoba B; Atienza-Navarro I; Lubian-Lopez S; Garcia-Alloza M
    Front Aging Neurosci; 2021; 13():741923. PubMed ID: 34975451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.
    Hierro-Bujalance C; Infante-Garcia C; Del Marco A; Herrera M; Carranza-Naval MJ; Suarez J; Alves-Martinez P; Lubian-Lopez S; Garcia-Alloza M
    Alzheimers Res Ther; 2020 Apr; 12(1):40. PubMed ID: 32264944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease.
    Ramos-Rodriguez JJ; Spires-Jones T; Pooler AM; Lechuga-Sancho AM; Bacskai BJ; Garcia-Alloza M
    Mol Neurobiol; 2017 Jul; 54(5):3428-3438. PubMed ID: 27177549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus.
    Ramos-Rodriguez JJ; Infante-Garcia C; Galindo-Gonzalez L; Garcia-Molina Y; Lechuga-Sancho A; Garcia-Alloza M
    Mol Neurobiol; 2016 May; 53(4):2685-97. PubMed ID: 26156287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell proliferation and neurogenesis alterations in Alzheimer's disease and diabetes mellitus mixed murine models.
    Hierro-Bujalance C; Del Marco A; José Ramos-Rodríguez J; Infante-Garcia C; Bella Gomez-Santos S; Herrera M; Garcia-Alloza M
    J Neurochem; 2020 Sep; 154(6):673-692. PubMed ID: 32068886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model.
    Guo C; Zhang S; Li JY; Ding C; Yang ZH; Chai R; Wang X; Wang ZY
    Sci Rep; 2016 Jul; 6():29396. PubMed ID: 27406855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid beta and diabetic pathology cooperatively stimulate cytokine expression in an Alzheimer's mouse model.
    Sankar SB; Infante-Garcia C; Weinstock LD; Ramos-Rodriguez JJ; Hierro-Bujalance C; Fernandez-Ponce C; Wood LB; Garcia-Alloza M
    J Neuroinflammation; 2020 Jan; 17(1):38. PubMed ID: 31992349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors.
    Bonds JA; Shetti A; Bheri A; Chen Z; Disouky A; Tai L; Mao M; Head BP; Bonini MG; Haus JM; Minshall RD; Lazarov O
    J Neurosci; 2019 Oct; 39(43):8576-8583. PubMed ID: 31527120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques.
    Natunen T; Martiskainen H; Marttinen M; Gabbouj S; Koivisto H; Kemppainen S; Kaipainen S; Takalo M; Svobodová H; Leppänen L; Kemiläinen B; Ryhänen S; Kuulasmaa T; Rahunen E; Juutinen S; Mäkinen P; Miettinen P; Rauramaa T; Pihlajamäki J; Haapasalo A; Leinonen V; Tanila H; Hiltunen M
    Mol Neurodegener; 2020 Nov; 15(1):66. PubMed ID: 33168021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages.
    Serrano FG; Tapia-Rojas C; Carvajal FJ; Cisternas P; Viayna E; Sola I; Munoz-Torrero D; Inestrosa NC
    Curr Alzheimer Res; 2016; 13(9):1017-29. PubMed ID: 26502813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing brain glucose uptake by Gypenoside LXXV ameliorates cognitive deficits in a mouse model of diabetic Alzheimer's disease.
    Meng X; Zhang Y; Li Z; Ma G; Zhang X; Zhang D; Cao W; Wang S; Cai Q; Cui P; Huang G
    Phytother Res; 2023 Feb; 37(2):611-626. PubMed ID: 36325883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models.
    Bignante EA; Ponce NE; Heredia F; Musso J; Krawczyk MC; Millán J; Pigino GF; Inestrosa NC; Boccia MM; Lorenzo A
    Neurobiol Aging; 2018 Apr; 64():44-57. PubMed ID: 29331876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1.
    Knight EM; Ruiz HH; Kim SH; Harte JC; Hsieh W; Glabe C; Klein WL; Attie AD; Buettner C; Ehrlich ME; Gandy S
    Acta Neuropathol Commun; 2016 Feb; 4():16. PubMed ID: 26916443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated amyloid angiopathy and related vascular alterations in a mixed murine model of Alzheimer´s disease and type two diabetes.
    Vargas-Soria M; Ramos-Rodriguez JJ; Del Marco A; Hierro-Bujalance C; Carranza-Naval MJ; Calvo-Rodriguez M; van Veluw SJ; Stitt AW; Simó R; Bacskai BJ; Infante-Garcia C; Garcia-Alloza M
    Fluids Barriers CNS; 2022 Nov; 19(1):88. PubMed ID: 36345028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.